Kidney Transplant Rejection Market Outlook Highlighting Demand Trends Through 2030

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Increase Is Anticipated For The Kidney Transplant Rejection Market Over The 2026–2030 Period?

The kidney transplant rejection market size has experienced robust growth recently. It is anticipated to increase from $3.51 billion in 2025 to $3.76 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.2%. This historical expansion can be ascribed to a surge in kidney transplant procedures, developments in histopathological assessment methods, broader access to immunosuppressive medicines, the proliferation of transplant center networks, and enhanced post-transplant patient survival rates.

The kidney transplant rejection market is projected to experience substantial expansion in the coming years, reaching a valuation of $5.01 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 7.4%. This anticipated growth is driven by several factors, including an escalating demand for tailored immunosuppression approaches, the wider integration of molecular diagnostics, the spread of precision medicine in transplant management, a heightened emphasis on ensuring long-term graft survival, and increased capital flow into transplant monitoring solutions. Key trends shaping the market during this period involve the increasing embrace of biomarker-driven rejection surveillance, a surge in genomics-based diagnostic techniques, continuous refinement of immunosuppressive treatment regimens, the development of non-invasive methods for rejection detection, and a stronger commitment to identifying chronic rejection early.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=33190&type=smp

What Key Drivers Are Influencing The Growth Of The Kidney Transplant Rejection Market?

An increasing occurrence of end-stage renal disease (ESRD) is projected to boost the expansion of the kidney transplant rejection market in the future. End-stage renal disease (ESRD) is defined as the ultimate, irreversible phase of chronic kidney disease where the kidneys are unable to function sufficiently without either dialysis or a kidney transplant. The prevalence of ESRD is increasing because of a rise in chronic conditions such as diabetes and hypertension, which gradually impair kidney function, leading to renal failure. The phenomenon of kidney transplant rejection necessitates sophisticated monitoring and treatment strategies, which directly aid in managing end-stage renal disease by helping transplanted kidneys remain viable and patients preserve their kidney health. As an illustration, data from September 2024, provided by the National Institute of Diabetes and Digestive and Kidney Diseases, a US government body, indicated that in 2023, over 808,000 individuals in the United States were afflicted with end-stage kidney disease (ESKD), also known as end-stage renal disease (ESRD). Of these, 68% were undergoing dialysis, while 32% had received a kidney transplant. Consequently, the growing occurrence of end-stage renal disease is propelling the expansion of the kidney transplant rejection market.

How Is The Kidney Transplant Rejection Market Segmented Across Key Categories?

The kidney transplant rejection market covered in this report is segmented –

1) By Rejection Type: Chronic Rejection; Acute Rejection

2) By Treatment: Immunosuppressive Drugs; Antibody-Mediated Rejection Therapies

3) By Diagnostic Approach: Biomarker-Based Diagnostics; Genomics-Based Diagnostics

4) By Therapeutics: Small Molecule Inhibitors; Biologic Therapies

5) By End-Users: Transplant Centers Or Hospitals; Diagnostic Laboratories; Pharmacies

Subsegments:

1) By Chronic Rejection: Antibody Mediated Chronic Rejection; Chronic Allograft Nephropathy; Interstitial Fibrosis And Tubular Atrophy; Vascular Chronic Rejection; Mixed Chronic Rejection

2) By Acute Rejection: Cellular Acute Rejection; Antibody Mediated Acute Rejection; Hyperacute Rejection; Mixed Acute Rejection; Vascular Acute Rejection

Which Upcoming Trends Are Expected To Influence The Kidney Transplant Rejection Market?

Leading companies within the kidney transplant rejection market are concentrating on creating advanced diagnostic methods, specifically noninvasive urinary biomarker testing, to facilitate the quicker, safer, and more precise identification of transplant rejection. This noninvasive method involves examining urine samples for molecular markers indicating kidney inflammation or rejection, thereby assisting medical professionals in promptly and safely pinpointing transplant complications without requiring invasive biopsies. An example of this is Thermo Fisher Scientific Inc., a US-based biotechnology firm, which introduced its CXCL10 testing service in May 2024, offering an advanced diagnostic option for individuals who have undergone kidney transplantation. The CXCL10 test identifies the CXCL10 chemokine present in urine, a substance connected to the early stages of transplant rejection and inflammation. This test provides results within 24 hours, allowing for more rapid clinical judgments, decreasing the necessity for unwarranted biopsies, and enhancing patient ease through its noninvasive sample collection method. Developed and validated by Thermo Fisher’s One Lambda Laboratories, this assay features a combination of high sensitivity, specificity, and user-friendliness in clinical environments, thereby contributing to enhanced post-transplant care and improved patient results.

Who Are The Top Companies Competing In The Kidney Transplant Rejection Market?

Major companies operating in the kidney transplant rejection market are F. Hoffmann-La Roche AG, Merck & Co. Inc., Sanofi SA, Novartis AG, Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., Takeda Pharmaceutical Company Limited, Amgen Inc., Asahi Kasei Corporation, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Biogen Inc., ChugAI Pharmaceutical Co. Ltd., Eurofins Scientific SE, Illumina Inc., Natera Inc., CareDx Inc., Azurity Pharmaceuticals Inc., Insight Molecular Diagnostics, and RenalytixAI plc.

Read the full kidney transplant rejection market report here:

https://www.thebusinessresearchcompany.com/report/kidney-transplant-rejection-market-report

Which Region Is Anticipated To See The Fastest Growth In The Kidney Transplant Rejection Market?

North America was the largest region in the kidney transplant rejection market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the kidney transplant rejection market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Kidney Transplant Rejection Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=33190&type=smp

Browse Through More Reports Similar to the Global Kidney Transplant Rejection Market 2026, By The Business Research Company

Kidney Transplant Market Report 2026

https://www.thebusinessresearchcompany.com/report/kidney-transplant-global-market-report

Organ Transplant Immunosuppressant Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/organ-transplant-immunosuppressant-drugs-global-market-report

Continuous Renal Replacement Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/continuous-renal-replacement-therapy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795